Based on the company's latest reports for September 2025, the current 12-month EPS is $9.92. Davita's earnings per share in 2024 was reported at $11.02, marking a rise from $7.62 in 2023. In the quarterly report ending on Sep 30, 2025, DVA's earnings per share amounted to $2.09.
Davita had an yealy earnings per share of $11.02, showing a rise of 44.6% from $7.62 recorded in 2023. The quarterly earnings per share for the period ending Sep 30, 2025, was $2.09, showing a 18.4% decline compared to the same quarter last year. The trailing twelve months EPS for DVA is $9.92 as of September 2025. Davita's full-year EPS for 2023 was $7.62, a 26.4% rise compared to the previous year.
In the past 12 months, Davita has recorded an earnings per share growth rate of -18.4% (YoY, quarterly). Across the past three years, the company had an average EPS annual growth rate of 5.8% per year. In the last five years, the company had an average annual EPS growth of 15.8%. When assessed over a ten-year period, DVA's average EPS annual growth was 12.4%.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| MD Mednax Inc | 11.21 | -63% | N/A | N/A |
| UHS Universal Health Services Inc | 11.69 | 65.8% | 12.7% | 13.4% |
| DVA Davita Inc | 12.21 | 44.6% | 5.8% | 15.8% |
| THC Tenet Healthcare Corp | 13.8 | 449.4% | 56.9% | N/A |
| LH Laboratory Corp Of America Holdings | 24.03 | 85.2% | -28.8% | 1.1% |
All data is based on quarterly TTM periods, unless otherwise specified.